Cited by 73Protein Kinase Regulation and GTPase SignalingImmunodeficiency and Autoimmune DisordersPlatelet Disorders and Treatments

The DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index; 1 of the 180 sources its claims cite were checked for support.

Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders

Open access
Troeger, Anja, Williams, David A.·2013·Experimental Cell Research

Abstract

The small guanosine triphosphotases (GTPases) Rho proteins are members of the Ras-like superfamily. Similar to Ras, most Rho GTPases cycle between active GTP-bound, and inactive GDP-bound conformations and act as molecular switches that control multiple cellular functions. While most Rho GTPases are expressed widely, the expression of Rac2 and RhoH are restricted to hematopoietic cells. RhoH is an atypical GTPase that lacks GTPase activity and remains in the active conformation. The generation of mouse knock-out lines has led to new understanding of the functions of both of these proteins in blood cells. The phenotype of these mice also led to the identification of mutations in human RAC2 and RHOH genes and the role of these proteins in immunodeficiency diseases. This review outlines the basic biology of Rho GTPases, focusing on Rac and RhoH and summarizes human diseases associated with mutations of these genes.

Overview

CoChat Summary

Written by AI from the paper’s full text.

TL;DR

This review summarizes the biology of the hematopoietic-restricted Rho GTPases Rac2 and RhoH and how mouse knockout models predicted human immunodeficiency phenotypes. It describes the dominant-negative RAC2 D57N mutation causing severe phagocytic immunodeficiency and homozygous RHOH truncation causing T cell defects with susceptibility to EV-HPV infections.

Key findings

  • Rac2 is hematopoietic-specific and required for neutrophil chemotaxis, superoxide production, and F-actin assembly; Rac2−/− mice show leukocytosis with neutrophilia, defective long-term HSC engraftment, and increased susceptibility to invasive fungal infections.
  • A spontaneous dominant-negative D57N RAC2 mutation (G169A) was identified in two patients with severe phagocytic immunodeficiency; both had life-threatening bacterial infections in infancy, leukocytosis with neutrophilia, absent pus at infection sites, and defective fMLP-induced F-actin formation, chemotaxis, and (in patient 1) superoxide production.
  • RhoH is an atypical GTPase that is GTPase-deficient and remains constitutively GTP-bound; Rhoh−/− mice show a block in T cell maturation at the DN3 and DP stages, T cell lymphopenia, and impaired Zap70 recruitment to the immunological synapse.
  • A homozygous Y38X RHOH mutation was found in two siblings with Epidermodysplasia verruciformis; they lacked naïve T cells and recent thymic emigrants, had reduced β7+ skin-homing T cells, and their immortalized T cells failed to proliferate or phosphorylate Zap70 in response to TCR stimulation.

Methods

  • Narrative review; no primary experimental data reported.
  • Synthesizes published mouse knockout studies (Rac2−/−, Rac1/Rac2 double knockout, Rhoh−/−) and human genetic findings (RAC2 D57N patients; RHOH Y38X family identified by homozygosity mapping with high-density SNP array and whole-exome sequencing).
  • Describes biochemical and cellular assays from cited work, including neutrophil chemotaxis, F-actin assembly, NADPH oxidase/superoxide production, TCR-stimulated proliferation, and Zap70 phosphorylation.

Limitations

  • As a review, it presents no new primary data; all findings are drawn from cited studies.
  • The authors state the relatively mild human phenotype of RHOH deficiency compared to the murine knockout is noteworthy, and that the potential role of RhoH in B cell malignancy "remains largely unexplored."
  • The authors note that Rac isoform functions and cross-compensation "may well differ depending on the cell type and species," and that the TCR signaling defect in RHOH-deficient patients "may contribute but likely does not sufficiently explain" the localized EV-HPV susceptibility.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.yexcr.2013.07.002

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

45 Not checked yet · 37 No full text of the sources · 18 Own result · 14 Own interpretation · 13 Check pending · 1 Supported so far

  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 43

Create a free account to see these claims.

Create a free account to see these assumptions.

74 more claims

Create a free account to see all 128 claims and to verify the 68 references still open.

See all claims — free account

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Research works printed but not linked: 3

  1. Gaidano, 2003, Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma, Blood, 102, 1833, 10.1182/blood-2002-11-3606 · DOI · Paper page
  2. Li, 2002, The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function, Mol. Cell. Biol., 22, 1158, 10.1128/mcb.22.4.1158-1171.2002 · DOI · Paper page
  3. Chae, 2008, Cross-talk between RhoH and Rac1 in regulation of actin cytoskeleton and chemotaxis of hematopoietic progenitor cells, Blood, 111, 2597, 10.1182/blood-2007-06-093237 · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Troeger, A., & Williams, D. A.
Affiliations
  • Heinrich Heine University Düsseldorf (DE)
  • Boston Children's Hospital (US)
Corresponding author
Williams, David A.
Venue
Experimental Cell Research
Publisher
Elsevier BV
Published
2013-09
Volume
319
Issue
15
Pages
2375-2383
ISSN
0014-4827 (ISSN-L)
OpenAlex
W2031545497
Cited by
73
References
79
Citations by year
2025: 5 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 5 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 4
FWCI
0.51
Type
journal article
Language
en
Open access
Locations
  • Experimental Cell Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (U54TR001005)
  • National Cancer Institute (R01CA113969)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
Rho GTPases, Rac2, RhoH, hematopoietic cells, immunodeficiency, mouse knockout models, hematologic disorders
MeSH terms
RAC2 GTP-Binding Protein, Actins, Animals, Cytoskeleton, Gene Expression Regulation, Hematologic Diseases, Hematopoiesis, Humans, Mutation, Transcription Factors, Signal Transduction, Mice, Knockout, rho GTP-Binding Proteins, rac GTP-Binding Proteins, Myeloid Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review